For-profit IRBs are on the rise—but at whose expense?

Over the last decade, institutional review boards have experienced a wave of commercialization, which for-profit IRBs now overseeing 70% of all U.S. clinical trials for drugs and medical devices.

The two leading IRBs are held in majority ownership by private equity firms, which are also investors in pharmaceutical and medical device companies. And from 2008-2014, the FDA reported twice as many violations and problems with commercial IRBs than with their nonprofit counterparts.

This raises serious questions about commercialized IRBs’ ability to provide ethical, unbiased reviews.

Salus IRB took a closer look at this important issue. Read the whitepaper.

Salus IRB
  • About Us
    • Our Boards
    • Your Salus Team
    • Mission and Values
    • Compliance Statement
    • Affiliations
    • News
    • Submission Forms >>
    • Review & Response Times >>
    • Request IRB Roster >>
  • Services
    • Single Site Research/Local Review
    • Multi-Site Research/Central IRB Services
    • Institutional Outsourcing
    • Global/International Review
    • Accelerated Phase I
    • Phase I Oncology
    • Investigator-Initiated/Sponsored Research
    • Minimal Risk Research
    • IRB Exempt Determinations
    • Other Services
    • Getting Started >>
    • Submission Forms >>
    • Contact Us >>
  • Why Salus
    • Getting Started >>
    • Submission Forms >>
    • Review & Response Times >>
  • Getting Started
    • Submission Forms
    • Template Study Documents
    • Review & Response Times
    • Resources
    • Training
    • Contact Us >>
    • Client Feedback Survey >>
  • Sponsors/CROs
    • Reporting Responsibilities
    • Resources
    • Training
    • Getting Started >>
    • Submission Forms >>
    • Review & Response Times >>
  • Investigators
    • Reporting Responsibilities
    • Resources
    • Training
    • Getting Started >>
    • Submission Forms >>
    • Review & Response Times >>
  • Research Participants
    • Participant Inquiries
    • Frequently Asked Questions
    • Resources
  • Resources
    • Thought Leadership
    • For-profit IRBs are on the rise—but at whose expense?
  • Contact Us
    • Client Feedback Survey
    • Salus IRB Team Member Recognition
855.300.0815 SafeSync GlobeSync

© 2022 Salus IRB All Rights Reserved.   •   Salus IRB Privacy Policy   •   Your California Privacy Rights  

Association for the Accredidation of Human Research Protection Programs, Inc.